Leerink Partners Reiterates Buy Rating for Eli Lilly
Leerink Partners maintains its buy rating on Eli Lilly with a $1,232 price target, a 1.98% upside from the current price.
Key Points
- Leerink Partners reiterated its buy rating on Eli Lilly (NYSE: LLY) with a price target of $1,232 on June 25, 2026.
- Leerink Partners's $1,232 price target implies 1.98% upside from Eli Lilly and Company's ($LLY) current $1,208.12 share price.
- Shares traded near $1,117.26 on Thursday with a market cap of about $982.8 billion and a P/E ratio of 39.19.
- Insider buying occurred on June 15, 2026, with small purchases by several insiders at around $1,129.35 per share.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 25, 2026, Leerink Partners reiterated its buy rating on Eli Lilly and Company (NYSE: LLY), setting a price target of $1,232. This decision comes as shares of Eli Lilly traded near $1,117.26 on Thursday.
Leerink Partners vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Analysts Set New Price Targets
On June 25, 2026, Leerink Partners maintained its buy rating for Eli Lilly, setting a price target of $1,232. This follows similar sentiments from other analysts like Jefferies, which maintained a buy rating with a $1,350 target on June 9, 2026. B of A Securities also kept a buy rating with a $1,251 target on May 26, 2026, while Barclays set a price target of $1,400 on May 5, 2026, maintaining its buy stance.
Eli Lilly and Company Stock Up 2.9%
Shares of Eli Lilly (NYSE: LLY) traded near $1,117.26 on Thursday. The company boasts a substantial market cap of approximately $982.8 billion. Eli Lilly has a price-to-earnings ratio of 39.19 and a forward P/E of 24.79. The stock has seen a 52-week low of $623.78 and a high of $1,182.73, with a 50-day moving average of $1,011.09 and a 200-day moving average of $966.09. The company maintains a current ratio of 1.50 and a debt-to-equity ratio of 139.02.
$LLY price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Eli Lilly and Company
Insider activity at Eli Lilly has been notable, with several small purchases occurring on June 15, 2026. Luciano Juan, Erik Fyrwald, Ralph Alvarez, and Gabrielle Sulzberger bought 14, 9, 11, and 4 shares, respectively, at an average price of $1,129.35. Additionally, Ilya Yuffa, EVP & Pres, LLY USA & Global Capabilities, sold 2,500 shares at $1,150.77 on June 10, 2026, in a planned transaction.
About Eli Lilly and Company
Eli Lilly and Company, headquartered in Indianapolis, Indiana, is a global healthcare leader in the pharmaceutical industry. The company, led by CEO Mr. David A. Ricks, employs around 50,000 people. It develops and markets a wide range of human pharmaceutical products, including treatments for diabetes, oncology, immunology, and more. With a history dating back to 1876, Eli Lilly continues to innovate in the healthcare sector.
Bottom Line
Leerink Partners' reiteration of its buy rating for Eli Lilly with a $1,232 price target underscores the firm's confidence in the company's future prospects. Investors often track analyst ratings for insights into potential stock movements. However, it's important to remember that such ratings represent a snapshot in time and may not reflect future changes in market conditions.
Get Eli Lilly and Company alerts
New 13F filings, insider trades, and analyst moves on $LLY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.